REVIEW An antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS. Ritonavir is a peptidomimetic inhibitor of both the HIV-1 and HIV-2 proteases. Inhibition of HIV protease renders the enzyme incapable of processing the gag-pol polyprotein precursor which leads to production of non-infectious immature HIV particles.
Cooper C, la Porte C, Tossonian H, Sampalis J, Ackad N, Conway B (2012). A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study. HIV Clin Trials. 13(4):179-88. PMID 22849960.
Morgan RE, Campbell SE, Suehira K, Sponseller CA, Yu CY, Medlock MM (2012). Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr. 60(2):158-64. PMID 22627182.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. CATEGORIES APIs and Bioactives > Antivirals, Antiretrovirals, HIV Protease Inhibitors